USFDA flags CGMP lapses at Dabur’s Silvassa plant; import alert remains in force
USFDA has issued a warning letter to Dabur India citing data-integrity, quality-control and manufacturing deficiencies at its Silvassa pharmaceutical facility. The plant remains on Import Alert 66-40 after a partial voluntary US recall, raising compliance and export-continuity risks.
What happened
USFDA issued Dabur India a warning letter over data integrity, quality-control and manufacturing lapses at its Silvassa pharmaceutical plant. The facility’s
Key facts
- USFDA inspection: January-December 16, 2026
- USFDA warning letter dated July 24, 2027
- Teleconference: May 13, 2026
- Voluntary recall: June 2, 2026
- Import Alert 66-40 effective June 5, 2026
- 15 working days to respond
Why this matters
Any partnership, acquisition or supply arrangement involving Dabur’s pharmaceutical operations should include heightened regulatory diligence, contingency sourcing and protections against prolonged US market-access disruption.
What to watch
- Publication of Dabur's warning-letter response and whether FDA accepts the proposed remediation timetable.
- Any FDA reinspection, Form 483 observations, follow-up warning letter, import-alert modification or import-alert removal.
- Expansion of the voluntary recall, new market withdrawals, adverse-event signals or product-quality complaints.
- Evidence of US sales disruption, inventory write-downs, remediation expenses, customer losses or revised guidance in company filings.
- Changes in senior quality, regulatory or plant leadership and the use of external compliance consultants or independent auditors.
- Appoint or empower an independent quality and data-integrity oversight team with direct board-level reporting.
- Complete a retrospective review of laboratory records, batch documentation, deviations, out-of-specification investigations and electronic audit trails.
- Engage FDA promptly on a detailed corrective and preventive action plan, including timelines, accountability and third-party verification.
- Assess inventory, customer contracts and revenue exposure tied to US shipments from the Silvassa site; qualify alternate manufacturing or supply routes where allowed.
- Increase disclosure around affected products, recall status, remediation milestones, potential provisions and expected export impact.